CTXR Citius Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1506251 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-11.1%
TTM EPS YoY64.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-70.3%
ROA-34.3%
ROIC (approx.)-89.3%
Asset turnover—
Leverage & solvency
Liabilities / assets46.6%
Debt / equity0.00x
Current ratio0.84x
Interest coverage-127.24x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-8.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-09-30 | FY2024*2024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY2021*2021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $90,000 | $90,000 |
| R&D expense | $9.16M | $11.91M | $14.82M | $17.66M | $12.24M |
| SG&A expense | $18.53M | $18.25M | $15.30M | $11.75M | $9.84M |
| Operating income | -$38.53M | -$42.00M | -$36.73M | -$33.32M | -$23.53M |
| Interest expense | $267,782 | — | — | — | $10,839 |
| Pretax income | -$38.68M | -$38.85M | -$31.97M | -$33.06M | -$23.05M |
| Income tax | $1.06M | $576,000 | $576,000 | $576,000 | $1,233 |
| Net income | -$37.43M | -$39.14M | -$32.54M | -$33.64M | -$23.05M |
| EBITDA | — | -$41.99M | -$36.73M | -$33.31M | -$23.53M |
| EPS (basic) | -3.38 | -5.97 | -5.57 | -0.23 | -0.23 |
| EPS (diluted) | -3.38 | -5.97 | -5.57 | -0.23 | -0.23 |
| Weighted avg. shares (diluted) | 11.07M | 6.73M | 6.05M | 146.08M | 108.60M |
| Balance sheet | |||||
| Cash & equivalents | $4.25M | $3.25M | $26.48M | $41.71M | $70.07M |
| Inventory | $22.29M | $8.27M | — | — | — |
| Current assets | $27.93M | $14.22M | $34.37M | $44.56M | $72.81M |
| PP&E, net | — | — | $1,432 | $4,100 | $7,023 |
| Goodwill | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M |
| Total assets | $130.94M | $116.65M | $103.61M | $114.00M | $142.43M |
| Current liabilities | $44.91M | $35.81M | $5.78M | $4.53M | $3.98M |
| Total liabilities | $53.41M | $42.55M | $12.18M | $10.57M | $9.65M |
| Shareholders' equity | $67.55M | $70.08M | $90.83M | $102.83M | $132.18M |
| Shares outstanding | 18.07M | 7.25M | 6.35M | 146.21M | 145.98M |
| Cash flow statement | |||||
| Operating cash flow | -$26.55M | -$28.20M | -$29.06M | -$28.36M | -$24.25M |
| Capital expenditure | — | — | — | — | $6,938 |
| Free cash flow | — | — | — | — | -$24.26M |
| Investing cash flow | -$5.75M | -$5.00M | — | — | -$40.01M |
| Financing cash flow | $33.30M | $9.97M | $13.83M | — | $120.47M |
| Depreciation & amortization | — | $1,432 | $2,668 | $2,923 | $1,492 |
| Stock-based compensation | $10.84M | $11.84M | $6.62M | $3.91M | $1.45M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.